Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150–4154.

    Article  CAS  PubMed  Google Scholar 

  3. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743–5750.

    Article  CAS  PubMed  Google Scholar 

  4. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010; 115: 2749–2754.

    Article  CAS  PubMed  Google Scholar 

  5. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348–2355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636–3643.

    Article  CAS  PubMed  Google Scholar 

  7. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225–234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981–8987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011; 25: 246–253.

    Article  CAS  PubMed  Google Scholar 

  12. Chou WC, Hou HA, Liu CY, Chen CY, Lin LI, Huang YN et al. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Ann Oncol 2011; 22: 696–704.

    Article  PubMed  Google Scholar 

  13. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 998–1004.

    Article  CAS  PubMed  Google Scholar 

  14. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van der Knaap MS et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 2010; 330: 336.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants NSC 96-2628-B002-013-MY2, 97-2314-B002-015-MY3, 97-2628-B-002-002-MY3, 98-2314-B-002-033-MY3, 100-2325-B-002-032, 100-2325-B-002-033- from the National Science Council (Taiwan), NHRI-EX97-9731BI from the National Health Research Institute, DOH100-TD-C-111-001 from the Department of Health (Taiwan), NTUH 98-S1052, NTUH 98-S1383 from the National Taiwan University Hospital and the YongLin Healthcare Foundation.

Author contributions

W-CC and H-FT designed the experiment. W-CC, K-YP, C-HK and H-FT analyzed the data and wrote the paper. W-CL, B-SK and WT provided important materials.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H-F Tien.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chou, WC., Peng, KY., Lei, WC. et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia 26, 527–529 (2012). https://doi.org/10.1038/leu.2011.215

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.215

Search

Quick links